- Conditions
- Genotype 1 Hepatitis C Virus
- Interventions
- harvoni
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 732
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
- Interventions
- Genotype-guided, Standard-of-Care
- Genetic · Other
- Lead sponsor
- University of Puerto Rico
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
- Drug · Other
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
- Conditions
- HCV (Genotype 1)
- Interventions
- INX-08189, Placebo matching with INX-08189, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Plymouth, Minnesota • San Antonio, Texas
- Conditions
- Chromosome Aberrations, Growth Hormone Deficiency, Hypomyelination
- Interventions
- Determination of growth hormone status, Measurement of growth, thyroid and sex hormone levels, Behavior and neuropsychometric evaluations, Audiological and ear, nose and throat examination, Magnetic resonance imaging of the brain, Dysmorphology evaluation, Neurology examination, Dental evaluation, Speech pathology evaluation, Psychiatric evaluation, Orthopedic evaluation, Ophthalmologic evaluation, Gastrointestinal evaluation
- Procedure
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1993 – 2040
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Heart Failure
- Interventions
- FDC I/H
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 19
- States / cities
- Tuscaloosa, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more
- Conditions
- Healthy Volunteers, Substance Use Disorders
- Interventions
- Not listed
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 847 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cystic Fibrosis
- Interventions
- VX-522 mRNA therapy, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Long Beach, California • Palo Alto, California + 9 more
- Conditions
- Fanconi Anemia
- Interventions
- Specimen Donation
- Diagnostic Test
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- ATTR Amyloidosis
- Interventions
- no intervention
- Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 52,121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Stanford, California • Chicago, Illinois • Bethesda, Maryland + 2 more
- Conditions
- Gaucher
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 20 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2031
- U.S. locations
- 3
- States / cities
- Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania
- Conditions
- PPAP, Spine Fusion
- Interventions
- Preoperative Genotyping
- Diagnostic Test
- Lead sponsor
- Senthil Sadhasivam
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- San Francisco, California • St. Petersburg, Florida • Indianapolis, Indiana + 1 more
- Conditions
- Osteogenesis Imperfecta, Short Stature
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 1 Day to 120 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- NO BI Drug administered
- Behavioral
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 18 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 34
- States / cities
- Bakersfield, California • Beverly Hills, California • Fountain Valley, California + 27 more
- Conditions
- Hepatitis C, HIV-1-infection, Liver Diseases
- Interventions
- Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
- Drug · Other
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- Depression
- Interventions
- AssureRx GeneSight genotyping results, Treatment as usual
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Interventions
- Biospecimen Collection, Genotyping, Survey Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years to 75 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Solid Tumors, Hematologic Cancers
- Interventions
- molecular profiling of tumors, Clinical Germline Analysis
- Genetic
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 18
- States / cities
- Bridgeport, Connecticut • Hartford, Connecticut • Norwalk, Connecticut + 13 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Irvine, California • Los Angeles, California • San Diego, California + 1 more
- Conditions
- Major Depressive Disorder
- Interventions
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Genetic · Other
- Lead sponsor
- Genomind, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
- Conditions
- Rhesus D Genotype
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Detroit, Michigan • New York, New York + 6 more